mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines
Copyright policy )mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines
Background and objective: Expression of genes involved in DNA repair and/or DNA synthesis, including ribonucleotide reductase M1 (RRM1) and excision repair cross‐complementation 1 (ERCC1) has been reported to be associated with chemosensitivity to platinum agents and gemcitabine. The aim of this study was to test whether similar associations would be seen between mRNA expression for the RRM1, ERCC1 and ERCC2 genes and in vitro chemosensitivity in lung cancer.Methods: Using a panel of 20 lung cancer cell lines, including 15 NSCLC and 5 small cell lung cancers (SCLC), the mRNA expression levels for the RRM1, ERCC1 and ERCC2 genes were examined by quantitative real‐time reverse transcription PCR. The in vitro cytotoxicity of cisplatin, carboplatin and gemcitabine was assessed using a tetrazolium‐based colorimetric assay (3‐[4,5‐dimethylthiazol‐2‐yl]‐2,5‐diphenyltetrazoliumbromide (MTT) assay).Results: Significantly, higher RRM1 mRNA expression was found in SCLC compared with NSCLC. However, there were no correlations between mRNA expression of the ERCC1, ERCC2 and RRM1 genes and chemosensitivity to cisplatin, carboplatin or gemcitabine.Conclusions: These in vitro results suggest that further studies are needed to evaluate the expression of the RRM1, ERCC1 and ERCC2 genes as predictive biomarkers for sensitivity to platinum agents and gemcitabine.
- Aichi Cancer Center Japan
- Nagoya University Japan
- Chubu University Japan
- National Cancer Research Institute United Kingdom
Lung Neoplasms, Ribonucleoside Diphosphate Reductase, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Antineoplastic Agents, Adenocarcinoma, In Vitro Techniques, Endonucleases, Deoxycytidine, Carboplatin, DNA-Binding Proteins, Inhibitory Concentration 50, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Carcinoma, Squamous Cell, Humans, RNA, Messenger, Carcinoma, Small Cell, Cisplatin, Drug Screening Assays, Antitumor
Lung Neoplasms, Ribonucleoside Diphosphate Reductase, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Antineoplastic Agents, Adenocarcinoma, In Vitro Techniques, Endonucleases, Deoxycytidine, Carboplatin, DNA-Binding Proteins, Inhibitory Concentration 50, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Carcinoma, Squamous Cell, Humans, RNA, Messenger, Carcinoma, Small Cell, Cisplatin, Drug Screening Assays, Antitumor
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).29 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!